Drug Profile
GM 1485
Alternative Names: GM-1485; GPI-1485; NIL-ALatest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator MGI GP
- Developer GliaMed
- Class Lactones; Macrolides; Neuroprotectants; Small molecules
- Mechanism of Action Immunophilin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Myocardial infarction
- Research Bone disorders; Cartilage disorders
- No development reported Wounds
- Discontinued Dementia; Erectile dysfunction; HIV-associated nephropathy; Parkinson's disease
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Wounds in USA (Topical)
- 20 Apr 2020 Preclinical development is ongoing for Wounds in USA (Topical) (GliaMed pipeline, April 2020)
- 20 Apr 2020 Early research in Bone disorders in USA (unspecified route) (GliaMed pipeline, April 2020)